🧪RNA Therapeutics (non-mRNA)
RNA-based medicines including siRNA, antisense oligonucleotides, and RNA interference therapies for genetic diseases.
Market Cap$964.5B
1D-2.20%
Companies237
Public Cos33
SECTOR MARKET CAP
$964.5B+16444.1%ALL
TOP COMPANIES
| # | Company | Country | Valuation | Ticker |
|---|---|---|---|---|
| 1 |  | United States | $851.4B | LLY |
| 2 |  | United States | $39.9B | ALNY |
| 3 |  | United States | $28.4B | BIIB |
| 4 |  | United States | $12.7B | IONS |
| 5 |  | United States | $10.7B | ARWR |
| 6 |  | Switzerland | $7.8B | BANB.SW |
| 7 |  | United States | $6.0B | PTCT |
| 8 |  | United States | $2.1B | SRPT |
| 9 |  | United States | $945.0M | SANA |
| 10 |  | United States | $851.8M | ABUS |
| 11 |  | United States | $699.7M | SLDB |
| 12 |  | United States | $470.0M | NGNE |
| 13 |  | United States | $418.9M | BNTC |
| 14 |  | United Kingdom | $325.9M | SLN |
| 15 |  | France | $259.8M | ALSEN.PA |
| 16 |  | United States | $254.3M | TRDA |
| 17 |  | Norway | $244.8M | CRNA.OL |
| 18 |  | United States | $212.4M | CAMP |
| 19 |  | United States | $170.2M | KRRO |
| 20 |  | United States | $147.7M | HURA |